Differential Response of Pelvic Bone Marrow Fluorodeoxyglucose Uptake in Patients Receiving Concurrent Chemoradiotherapy.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
10 2023
Historique:
received: 28 07 2022
revised: 01 05 2023
accepted: 01 06 2023
medline: 11 9 2023
pubmed: 21 6 2023
entrez: 20 6 2023
Statut: ppublish

Résumé

Irradiation of pelvic bone marrow (PBM) at the level of the typical low dose bath of intensity-modulated radiotherapy delivery (10-20 Gy) is associated with an increased risk of haematological toxicity, particularly when combined with concurrent chemotherapy. Although sparing of the whole of the PBM at a 10-20 Gy dose level is unachievable, it is known that PBM is divided into haematopoietically active and inactive regions that are identifiable based on the threshold uptake of [ Active and inactive PBM were contoured on baseline PET-CT and using deformable registration mapped onto mid-treatment PET-CT. Volumes were cropped to exclude definitive bone, voxel SUV extracted and the change between scans calculated. Change was compared using Mann-Whitney U testing. Active and inactive PBM were shown to respond differentially to concurrent chemoradiotherapy. The median absolute response of active PBM for all patients was -0.25 g/ml, whereas the median inactive PBM response was -0.02 g/ml. Significantly, the inactive PBM median absolute response was shown to be near zero with a relatively unskewed distribution (0.12). These results would support the definition of active PBM as FDG uptake greater than the mean of the whole structure as being representative of underlying cell physiology. This work would support the development of atlas-based approaches published in the literature to contour active PBM based on the current definition as being suitable.

Identifiants

pubmed: 37339923
pii: S0936-6555(23)00214-5
doi: 10.1016/j.clon.2023.06.001
pii:
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D
Radiopharmaceuticals 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e622-e627

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Auteurs

M Robinson (M)

Department of Clinical Oncology, Oxford University Hospitals NHS Trust, Oxford, UK; Department of Oncology, University of Oxford, Oxford, UK. Electronic address: maxwell.robinson@ouh.nhs.uk.

R Muirhead (R)

Department of Clinical Oncology, Oxford University Hospitals NHS Trust, Oxford, UK.

D R McGowan (DR)

Department of Oncology, University of Oxford, Oxford, UK; Department of Medical Physics and Clinical Engineering, Oxford University Hospitals NHS Trust, Oxford, UK.

K-Y Chu (KY)

Department of Clinical Oncology, Oxford University Hospitals NHS Trust, Oxford, UK; Department of Oncology, University of Oxford, Oxford, UK.

C Jacobs (C)

Department of Clinical Oncology, Oxford University Hospitals NHS Trust, Oxford, UK.

M A Hawkins (MA)

Department of Medical Physics and Biomedical Engineering, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH